Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Trial Details

NCT ID

NCT05019690

Phase

PHASE1 / PHASE2

Sponsor

Fujian Cancer Hospital

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• Apatinib Mesylate
• Albumin-Bound Paclitaxel

Locations (sample)

• Fuzhou, Fujian, China|26.06139,119.30611

Key Eligibility Criteria

• Volunteered to participate in the study, signed the informed consent form. 2.Aged 18-75 years,female. 3.Histologically or pathologically confirmed …
• Primary tumor stage determined by standard evaluation methods: CT0-4 /N0-3/M1;
• Pathologically confirmed breast cancer with negative HER2 expression, defined as \< 10% immunoreactive cells with an IHC score of + or -,or in situ…
• Negative hormone receptor status (ER and PgR) is known, which is defined as \< 1% detected by immunohistochemistry;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.